VTN and neoplasm: Activation of complement proteins was thought to be a tumour surveillance mechanism, given the fundamental role of complement proteins against noxious pathogens and the clinical benefit of mAb-based immunotherapy by triggering complement-dependent cytotoxicity towards tumour cells (57, 58).